These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 26069307)

  • 1. Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival.
    Etchebehere EC; Araujo JC; Fox PS; Swanston NM; Macapinlac HA; Rohren EM
    J Nucl Med; 2015 Aug; 56(8):1177-84. PubMed ID: 26069307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of Skeletal Tumor Burden on 18F-Fluoride PET/CT.
    Rohren EM; Etchebehere EC; Araujo JC; Hobbs BP; Swanston NM; Everding M; Moody T; Macapinlac HA
    J Nucl Med; 2015 Oct; 56(10):1507-12. PubMed ID: 26135112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT Predicts Bone Marrow Failure After 223Ra Therapy.
    Etchebehere EC; Araujo JC; Milton DR; Erwin WD; Wendt RE; Swanston NM; Fox P; Macapinlac HA; Rohren EM
    Clin Nucl Med; 2016 Apr; 41(4):268-73. PubMed ID: 26828141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687.
    Yu EY; Duan F; Muzi M; Deng X; Chin BB; Alumkal JJ; Taplin ME; Taub JM; Herman B; Higano CS; Doot RK; Hartfeil D; Febbo PG; Mankoff DA
    J Nucl Med; 2015 Mar; 56(3):354-60. PubMed ID: 25635138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Final Outcome of 223Ra-therapy and the Role of 18F-fluoride-PET in Response Evaluation in Metastatic Castration-resistant Prostate Cancer-A Single Institution Experience.
    Kairemo K; Milton DR; Etchebehere E; Rohren EM; Macapinlac HA
    Curr Radiopharm; 2018; 11(2):147-152. PubMed ID: 29956640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uptake of Radium-223 Dichloride and Early [
    Letellier A; Johnson AC; Kit NH; Savigny JF; Batalla A; Parienti JJ; Aide N
    Mol Imaging Biol; 2018 Jun; 20(3):482-491. PubMed ID: 29027074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18F-FDG PET/CT is a prognostic biomarker in patients affected by bone metastases from breast cancer in comparison with 18F-NaF PET/CT.
    Piccardo A; Puntoni M; Morbelli S; Massollo M; Bongioanni F; Paparo F; Altrinetti V; Gonella R; Gennari A; Iacozzi M; Sambuceti G; DeCensi A
    Nuklearmedizin; 2015; 54(4):163-72. PubMed ID: 26165806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline
    García Vicente AM; González García B; Amo-Salas M; García Carbonero I; Cassinello Espinosa J; Gómez-Aldaraví Gutierrez JL; Suarez Hinojosa L; Soriano Castrejón Á
    Clin Transl Oncol; 2019 Mar; 21(3):289-297. PubMed ID: 30006674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of baseline 18F-sodium fluoride and 18F-choline PET activity for identifying responders to radium-223 treatment in castration-resistant prostate cancer bone metastases.
    Donners R; Tunariu N; Tovey H; Hall E; Chua S; Cook G; Du Y; Blackledge MD; Parker CC; Koh DM
    Eur Radiol; 2024 Feb; 34(2):1146-1154. PubMed ID: 37615760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-Fluoride PET/CT tumor burden quantification predicts survival in breast cancer.
    Brito AE; Santos A; Sasse AD; Cabello C; Oliveira P; Mosci C; Souza T; Amorim B; Lima M; Ramos CD; Etchebehere E
    Oncotarget; 2017 May; 8(22):36001-36011. PubMed ID: 28415595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative Assessment of Early [
    Harmon SA; Perk T; Lin C; Eickhoff J; Choyke PL; Dahut WL; Apolo AB; Humm JL; Larson SM; Morris MJ; Liu G; Jeraj R
    J Clin Oncol; 2017 Aug; 35(24):2829-2837. PubMed ID: 28654366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is interim
    Etchebehere E; Brito AE; Kairemo K; Rohren E; Araujo J; Macapinlac H
    Radiol Bras; 2019; 52(1):33-40. PubMed ID: 30804613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Volume-metabolic Combined Parameters from (18)F-FDG PET/CT May Help Predict the Outcomes of Cervical Carcinoma.
    Sun Y; Lu P; Yu L
    Acad Radiol; 2016 May; 23(5):605-10. PubMed ID: 26853968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective Study of Serial
    Peterson LM; O'Sullivan J; Wu QV; Novakova-Jiresova A; Jenkins I; Lee JH; Shields A; Montgomery S; Linden HM; Gralow J; Gadi VK; Muzi M; Kinahan P; Mankoff D; Specht JM
    J Nucl Med; 2018 Dec; 59(12):1823-1830. PubMed ID: 29748233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interim and end-treatment
    García Vicente AM; Amo-Salas M; Cassinello Espinosa J; Gómez Díaz R; Soriano Castrejón Á
    Sci Rep; 2021 Apr; 11(1):7389. PubMed ID: 33795764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis measured by 18F-FDG PET/CT in salivary gland carcinomas.
    Ryu IS; Kim JS; Roh JL; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    J Nucl Med; 2013 Jul; 54(7):1032-8. PubMed ID: 23670902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Prognostic Value of Quantitative Bone SPECT/CT Before
    Dittmann H; Kaltenbach S; Weissinger M; Fiz F; Martus P; Pritzkow M; Kupferschlaeger J; la Fougère C
    J Nucl Med; 2021 Jan; 62(1):48-54. PubMed ID: 32444369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [(18)F]FDG-PET/CT metabolic parameters as useful prognostic factors in cervical cancer patients treated with chemo-radiotherapy.
    Herrera FG; Breuneval T; Prior JO; Bourhis J; Ozsahin M
    Radiat Oncol; 2016 Mar; 11():43. PubMed ID: 26984385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer.
    Jadvar H; Desai B; Ji L; Conti PS; Dorff TB; Groshen SG; Pinski JK; Quinn DI
    J Nucl Med; 2013 Aug; 54(8):1195-201. PubMed ID: 23785174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.